Clinical Trial Update: Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating azacitidine with carboplatin and paclitaxel for newly diagnosed ovarian cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Loyola University | Conditions: Ovarian Cancer | Phase 1 | Status: WITHDRAWN